JP2020530831A5 - - Google Patents

Info

Publication number

JP2020530831A5

JP2020530831A5 JP2019572817A JP2019572817A JP2020530831A5 JP 2020530831 A5 JP2020530831 A5 JP 2020530831A5 JP 2019572817 A JP2019572817 A JP 2019572817A JP 2019572817 A JP2019572817 A JP 2019572817A JP 2020530831 A5 JP2020530831 A5 JP 2020530831A5

Authority

JP

Japan

Prior art keywords

therapeutic agent

hormone

agent according

crf

receptor antagonist

Prior art date

2018-08-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 27
• 229940124597 therapeutic agent Drugs 0.000 claims 27
• 208000005676 Adrenogenital syndrome Diseases 0.000 claims 12
• 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 12
• 239000005556 hormone Substances 0.000 claims 12
• 229940088597 hormone Drugs 0.000 claims 12
• 239000002464 receptor antagonist Substances 0.000 claims 10
• 229940044551 receptor antagonist Drugs 0.000 claims 10
• 150000003839 salts Chemical class 0.000 claims 9
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims 5
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 5
• 101800000414 Corticotropin Proteins 0.000 claims 5
• 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 5
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 5
• 229960000258 corticotropin Drugs 0.000 claims 5
• 239000003862 glucocorticoid Substances 0.000 claims 3
• AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 239000010419 fine particle Substances 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims 1
• 241000282412 Homo Species 0.000 claims 1
• 229960005471 androstenedione Drugs 0.000 claims 1
• AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims 1
• 239000002775 capsule Substances 0.000 claims 1
• 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims 1